Exact Sciences (NASDAQ:EXAS) Earns Outperform Rating from William Blair

William Blair reaffirmed their outperform rating on shares of Exact Sciences (NASDAQ:EXAS) in a report issued on Thursday morning,RTT News reports.

Several other analysts have also recently commented on the company. Benchmark lowered their price target on Exact Sciences from $67.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Canaccord Genuity Group lowered their price target on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Citigroup cut their price target on Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Sanford C. Bernstein boosted their price target on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, TD Cowen cut their price target on Exact Sciences from $90.00 to $82.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Exact Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $74.47.

Exact Sciences Trading Down 0.3 %

NASDAQ:EXAS opened at $52.91 on Thursday. The company has a market capitalization of $9.79 billion, a PE ratio of -45.22 and a beta of 1.27. The company has a quick ratio of 1.93, a current ratio of 2.12 and a debt-to-equity ratio of 0.72. Exact Sciences has a 52-week low of $40.62 and a 52-week high of $79.62. The stock has a fifty day simple moving average of $64.79 and a 200-day simple moving average of $55.84.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The company had revenue of $708.66 million for the quarter, compared to analysts’ expectations of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The company’s revenue was up 12.8% on a year-over-year basis. On average, equities research analysts expect that Exact Sciences will post -1.08 earnings per share for the current fiscal year.

Insider Activity at Exact Sciences

In other Exact Sciences news, CEO Kevin T. Conroy purchased 19,500 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were bought at an average cost of $51.35 per share, with a total value of $1,001,325.00. Following the transaction, the chief executive officer now directly owns 1,074,191 shares in the company, valued at approximately $55,159,707.85. This represents a 1.85 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Brian Baranick sold 929 shares of Exact Sciences stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at approximately $893,060. This represents a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.36% of the stock is owned by company insiders.

Institutional Trading of Exact Sciences

Several institutional investors have recently modified their holdings of EXAS. UniSuper Management Pty Ltd grew its holdings in shares of Exact Sciences by 100.0% during the 1st quarter. UniSuper Management Pty Ltd now owns 2,600 shares of the medical research company’s stock worth $180,000 after purchasing an additional 1,300 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of Exact Sciences by 5.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 207,364 shares of the medical research company’s stock worth $14,361,000 after purchasing an additional 10,356 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Exact Sciences during the 1st quarter worth approximately $67,000. Advisors Asset Management Inc. grew its holdings in shares of Exact Sciences by 25.9% during the 1st quarter. Advisors Asset Management Inc. now owns 36,779 shares of the medical research company’s stock worth $2,540,000 after purchasing an additional 7,574 shares in the last quarter. Finally, BOKF NA grew its holdings in shares of Exact Sciences by 28.2% during the 1st quarter. BOKF NA now owns 22,338 shares of the medical research company’s stock worth $1,573,000 after purchasing an additional 4,909 shares in the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.